Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.88 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL6266601 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL28251884 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Mucic Acid SCHEMBL28031215 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL11850213 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL29093017 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL28112681 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL3725635 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Mucic Acid SCHEMBL28205033 | 1.00 | LMNA (0.88) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL28115533 | 0.98 | LMNA (0.84) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 | |
| Gluconic Acid SCHEMBL23647355 | 0.96 | LMNA (0.80) | LMNAPDE4AUSP2SLCO1B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-112566920-A | Improved protein recovery | 百时美施贵宝公司 | 2021-03-26 | — | — | CN | claimed |
| US-10287665-B2 | Dry lubricant for zinc coated steel | HENKEL AG & CO. KGAA (DE) | 2019-05-14 | — | — | US | claimed |
| CN-118354789-A | Anti-glyco-cMET antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118355031-A | Anti-saccharide-LAMP 1 antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118354788-A | Anti-glyco-MUC 4 antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114177308-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-111479828-B | Anti-saccharide-MUC 1 antibodies and uses thereof | GO医疗股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024133858-A1 | ANTIBODIES FOR USE AS COAGULANTS | JULIUS-MAXIMILIANS-UNIVERSITÄT-WÜRZBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209094-A1 | NEW STABLE ANTI-VISTA ANTIBODY | PIERRE FABRE MEDICAMENT (FR) | 2024-06-27 | — | — | US | disclosed |
| EP-0386106-A1 | GAMMA INTERFERON FORMULATION. | GENENTECH INC (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989007945-A1 | HUMAN RELAXIN FORMULATION | GENENTECH, INC. (US) | 1989-09-08 | — | — | WO | disclosed |
| WO-1989004177-A1 | GAMMA INTERFERON FORMULATION | GENENTECH, INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0284249-A1 | Lyophilized lymphokine composition | INTERFERON SCIENCES, INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4675184-A | VIRICIDES | 501 Sunstar Kabushiki Kaisha (JP) | 1987-06-23 | — | — | US | disclosed |
| EP-0080879-B1 | PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON IN STABLE STATE | SUNSTAR KABUSHIKI KAISHA (JP) | 1986-10-01 | — | — | EP | disclosed |
| US-4605555-A | INTERFERON, POLYHYDRIC SUGAR ALCOHOL, ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| US-4605556-A | APPLYING INTERFERON, POLYHYDRIC SUGAR ALCOHOL, AND ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0080879-A2 | Pharmaceutical composition containing interferon in stable state | SUNSTAR KABUSHIKI KAISHA (JP) | 1983-06-08 | — | — | EP | disclosed |